Blow To Roche Growth Prospects As TIGIT Lung Cancer Trial Fails
Cancer Combination Fails In Phase III
Failure of the tiragolumab plus Tecentriq combination in first line NSCLC patients is a blow to Roche’s immunotherapy aspirations, and its long-term growth strategy.
You may also be interested in...
In this week's podcast version of Five Must-Know Things: Pfizer to boost migraine presence via M&A; Roche’s immunotherapy ambitions take a hit; Biogen’s CEO search gets more complicated; Stoffels lays out new strategy for Galapagos; and mixed results for Japanese majors.
After two failures in a row from Roche, the TIGIT hypothesis is looking shaky, but it is too early to write off the class yet.
Tiragolumab missed several endpoints in a Phase III metastatic SCLC study, and hopes now rest on its success in NSCLC which presents the bigger market opportunity for the lead candidate in this closely watched new drug class.